MEDICAL MARVELS.

Their latest disruption: Starting in July, the company will sell its first so-called biosimilar drug, Yusimry, an alternative to the immunology drug Humira, one of the bestselling medications of all time, at a cost of $569.27 plus dispensing and shipping fees, vs. $6,922 for a similar dosage of Humira. MORE THAN ONE-THIRD OF AMERICANS, including nearly half of those with annual incomes below $50,000, have skipped taking prescribed drugs because of high prices - something former radiologist Alex Oshmyan-sky witnessed firsthand among his patients, sometimes with devastating health consequences. When Shkreli, a former pharmaceutical executive, raised the price of Dara-prim, a lifesaving drug used to treat parasitic infections, by 5,400 percent from $13.50 a pill to $750 in 2015, Oshmyansky decided he would take on price gouging by the pharmaceutical industry himself by selling off-patent drugs at manufacturing costs. M.G. MAKING MEDICINE MORE AFFORDABLE FOR ALL Alex Oshmyansky & Mark Cuban CO-FOUNDERS, MARK CUBAN COST PLUS DRUG CO. [Extracted from the article]

Copyright of Newsweek Global is the property of Newsweek Publishing LLC and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)